Lilly’s exenatide study shows possible benefits

Lilly’s study of exenatide has revealed further insight into its possible benefits.

The pharmaceutical company conducted the recent trial along with Amylin and Alkermes to test the once-weekly, investigational diabetes therapy compared to other medications for the disease.

During the 26-week clinical-study, 491 patients with type two of the condition were given either the tested drug or two other medications that are commonly used for the illness – sitagliptin and pioglitazone.

After completing the course, patients who had taken exenatide every seven days showed a statistically significant reduction in A1C.

Dr Jim Malone, global medical director for the drug at Lilly, said the results of the investigation had given them a greater indication into the treatment’s potential.

“Our goal is to clearly understand how exenatide once-weekly compares to other diabetes therapies and be able to articulate, through the data, these differences to patients and their healthcare providers,” he commented.

Last month, Lilly announced a study of mGlu2/3 for treating those suffering from acute schizophrenia showed it to be indifferent compared to the placebo.